Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases

Pertuzumab, a humanized antibody drug, has improved outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, when administered in combination with trastuzumab and other chemotherapies. Cardiotoxicity due to trastuzumab is widely recognized, while data on pert...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Mayuko, Horimoto, Yoshiya, Sasaki, Ritsuko, Miyazaki, Sakiko, Orihata, Gotaro, Saito, Mitsue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983593/
https://www.ncbi.nlm.nih.gov/pubmed/33776683
http://dx.doi.org/10.1159/000513002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983593/
https://www.ncbi.nlm.nih.gov/pubmed/33776683
http://dx.doi.org/10.1159/000513002

Ejemplares similares